Predicting chemotherapy response in gastric cancer
Part of Cancer, Digestive system clinical trials.
This research study analyzes tumor tissue samples to understand why some patients respond better to chemotherapy after gastric cancer surgery. By studying how genes are processed in cancer cells, researchers hope to predict which patients will benefit most from treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with stage II or III gastric cancer (confirmed by biopsy)
- Had surgery to remove the stomach cancer
- Received chemotherapy after surgery (a type called 5-FU based)
- Tumor tissue sample available for the study to examine
- No history of other types of cancer
- Tissue sample must be good quality and not contaminated
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses advanced imaging (ultrasound and CT) plus a blood test to predict how well your stomach cancer will respond to chemotherapy given before surgery. The goal is to personalize your treatment and improve outcomes.
This study looks at stomach (or stomach–esophagus junction) cancer tissue, treatment details, and patient-reported experiences to better predict how you may respond to standard chemotherapy. It may help personalize future treatment by identifying markers that connect your tumor environment and your expected outcomes.
This study looks for ways to predict whether neoadjuvant chemotherapy (chemo given before surgery) will work well in people with locally advanced stomach cancer. It may help doctors choose the best treatment plan sooner based on your test results.
This trial tests whether skipping chemotherapy after surgery is safe and effective for some patients with gastric cancer. If your tumor responded very well or very poorly to the pre-surgery chemotherapy, you might be able to avoid more chemo.
This study looks at samples of blood and tissue from people with advanced stomach cancer that has spread to the belly lining. The goal is to find markers that predict how well a treatment combining HIPEC (heated chemotherapy in the belly) with immunotherapy (drugs that help your immune system fight cancer) works.
This trial tests a computer-based model that uses CT scans, endoscopic images, and biopsy tissue to predict how well stomach cancer will respond to chemotherapy given before surgery. The goal is to help doctors choose the best treatment for each patient.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.